There are currently 297 active clinical trials seeking participants for Cancer research studies. The states with the highest number of trials for Autism participants are California, Texas, New York and Florida.
Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
NCT02090530
Recruiting
Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
Gender:
All
Ages:
18 years and above
Trial Updated:
09/14/2023
Locations: Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Cancer
Register for Updates
Enhancing Cancer Care Of Rural Dwellers
NCT04758338
Recruiting
Through a multi-level remote intervention, the Vanderbilt-Ingram Cancer Center (VICC) seeks to improve comprehensive cancer care delivery to patients residing in rural communities with persistent poverty. We plan to do this by using telehealth to broaden the reach of our NCI-designated comprehensive cancer center in these communities
Gender:
All
Ages:
21 years and above
Trial Updated:
11/16/2023
Locations: Baptist Cancer Center- Golden Triangle Columbus, Columbus, Mississippi +4 locations
Conditions: Cancer
Register for Updates
Building Family Caregiver Skills Using a Simulation-Based Intervention for Care of Cancer Patients
NCT04055948
Recruiting
The purpose of this study is to learn whether an education and support program can help caregivers feel more confident in technical and communication skills needed to care for a person with cancer. Patients with cancer and their caregivers face many challenges. These include learning about cancer and its treatment, coping with symptoms from illness and treatment side effects, making adjustments to usual activities, and managing the emotional effects of having a serious illness. This study is tes... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/26/2023
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio +1 locations
Conditions: Cancer
Register for Updates
A Pilot Feasibility Trial of a Tailored Intervention to Improve Adherence in Adolescents and Young Adults With Cancer
NCT05706610
Recruiting
A pilot feasibility randomized clinical trial comparing a tailored intervention to uniform standard of care will be conducted. A total of 40 AYAs with cancer will be randomized to one of the two programs. Data will be collected to explore the hypotheses that the intervention meets pre-established enrollment, retention, fidelity, and data completion feasibility criteria and that AYAs will rate the intervention as easy to use and acceptable.
Gender:
All
Ages:
Between 15 years and 24 years
Trial Updated:
09/20/2023
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio +2 locations
Conditions: Cancer, Adherence, Medication
Register for Updates
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT05997017
Recruiting
A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida +7 locations
Conditions: Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor, Recurrent Endometrial Carcinoma, Endometrioid Endometrial Cancer
Register for Updates
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT03768063
Recruiting
This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Univ of Alabama at Birmingham; UAB Comprehensive Cancer Ctr, Birmingham, Alabama +190 locations
Conditions: Cancer
Register for Updates
Connect for Cancer Prevention Study (Connect)
NCT04609072
Recruiting
Background: The National Cancer Institute, part of the National Institutes of Health, has partnered with nine health care systems across the U.S. to establish the Connect for Cancer Prevention Study. While researchers have made important discoveries, there is more to learn to lower the number of people affected by cancer. By taking part in Connect, participants can help researchers learn how the way we live, our genetics, and our health history may affect cancer risk. Objective: To study and... Read More
Gender:
All
Ages:
Between 30 years and 70 years
Trial Updated:
04/17/2024
Locations: Kaiser Permanente Colorado, Denver, Colorado +8 locations
Conditions: Cancer, General Research Use
Register for Updates
Patient-Centered Assessment of Symptoms and Outcomes
NCT03952624
Recruiting
Background: The cause of fatigue is not well understood. It can be felt differently by different people. Some people think there are different types of fatigue, with different causes. Researchers think a therapy to treat one type of fatigue in one condition should be able to treat that type of fatigue in other conditions. Objective: To understand the types of fatigue. Eligibility: Adults 18 and older who have felt fatigue for more than a month, and non-fatigued adults Design: Participants... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Fatigue, Cancer, CFS, ME/CFS, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Lupus, Systemic Lupus Erthematosus, Sjogrens
Register for Updates
Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors
NCT06014658
Recruiting
This is a first-in-human (FIH), open label Phase 1/1b study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum tolerated dose (MTD) of MBRC-101 at one 1 or more dosing regimens. Phase 1b will evaluate the safety and preliminary clinical activity of MBRC-101 at potential OBRDs. Phase 1 and Phase 1b will both characterize single and multiple-dose PK profiles and evaluate inci... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California +6 locations
Conditions: Cancer
Register for Updates
Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and Cancer Survivors
NCT01231932
Recruiting
Background: - Fatigue is a common side effect of cancer and its treatment. Up to 96% of patients with cancer have fatigue. The cause of fatigue in people with cancer or those receiving treatment is poorly understood, making fatigue hard to treat. More research is necessary to understand why cancer patients experience fatigue. Previous research has shown that fatigue may be caused by a number of factors, including problems with the immune system response of the body while undergoing cancer treat... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/16/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cancer, Fatigue, Prostate Cancer, Breast Cancer, Cancer Survivor
Register for Updates
Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy
NCT00026650
Recruiting
Background: This protocol acknowledges that it is in the interest of the NIH and ROB, as well as our patients, to continue to follow those who have been treated with radiotherapy at ROB and are not otherwise eligible for current active research protocols. It also provides a mechanism for the correlation and interpretation of disparate data for research into the long term side effects and outcomes for a variety of disease entities and treatments, such as combined modality treatment, MoAb, PDT, r... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cancer
Register for Updates
Tumor Related Epilepsy
NCT02639325
Recruiting
Background: Some people with brain tumors have seizures related to the tumor. This is called tumor-related epilepsy. Usually brain tumors are treated by removing as much of the brain tumor as possible without causing problems. Researchers think this may improve the outcome for people with brain tumors. It may completely relieve or greatly reduce the number of seizures they have. Objectives: To evaluate people with brain tumors that are associated with seizures and to offer surgical treatment.... Read More
Gender:
All
Ages:
Between 8 years and 99 years
Trial Updated:
04/16/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Epilepsy, Cancer, Brain Neoplasm
Register for Updates